PMID- 27283238
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Linking)
VI  - 35
IP  - 4
DP  - 2017 Dec
TI  - SERUM metabolomics of acute lymphoblastic leukaemia and acute myeloid leukaemia 
      for probing biomarker molecules.
PG  - 769-777
LID - 10.1002/hon.2313 [doi]
AB  - Acute leukaemia (AL) is a critical neoplasm of white blood cells. Diagnosing AL 
      requires bone marrow puncture procedure, which many patients do not consent to 
      for it is invasive. Hence sensitive and specific early diagnostic biomarkers are 
      essential for non-invasive diagnosis, new therapeutics and improving the disease 
      prognosis. To differentiate the metabolic alterations associated with acute 
      lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML), we investigated 
      serum of ALL and AML patients in comparison with two controls using gas 
      chromatography coupled with triple quadrupole tandem mass spectrometry and 
      multivariate statistical analysis. Twenty seven out of 1425 metabolites were 
      found differentiative among ALL, AML, aplastic anaemia (APA) patients and healthy 
      control using p-value </= 0.001. ALL is the most dissimilar group from other three 
      groups as in hierarchical clustering showed 72.1% dissimilarity. Model generation 
      using PLSDA gave an overall accuracy of 91.9%. This study helps in metabolic 
      fingerprinting of control and disease serum at high significance levels and could 
      be used for early diagnosing of AL. Based on pathways analysis, fatty acid 
      metabolism is deregulated in patients with AL and may represent an underlying 
      metabolic pathway associated with disease progression. Copyright (c) 2016 John 
      Wiley & Sons, Ltd.
CI  - Copyright (c) 2016 John Wiley & Sons, Ltd.
FAU - Musharraf, Syed Ghulam
AU  - Musharraf SG
AD  - Dr. Panjwani Center for Molecular Medicine and Drug Research, International 
      Center for Chemical and Biological Sciences, University of Karachi, Karachi, 
      75270, Pakistan.
AD  - H.E.J. Research Institute of Chemistry, International Center for Chemical and 
      Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
FAU - Siddiqui, Amna Jabbar
AU  - Siddiqui AJ
AD  - H.E.J. Research Institute of Chemistry, International Center for Chemical and 
      Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
FAU - Shamsi, Tahir
AU  - Shamsi T
AD  - Dr. Panjwani Center for Molecular Medicine and Drug Research, International 
      Center for Chemical and Biological Sciences, University of Karachi, Karachi, 
      75270, Pakistan.
AD  - National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, 
      Pakistan.
FAU - Naz, Arshi
AU  - Naz A
AD  - National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, 
      Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20160610
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*diagnosis/pathology
MH  - Male
MH  - Metabolomics/*methods
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/pathology
OTO - NOTNLM
OT  - GC-QQQ-MS
OT  - acute leukaemia
OT  - chemometric analysis
OT  - human serum
OT  - metabolomics
EDAT- 2016/06/11 06:00
MHDA- 2018/01/06 06:00
CRDT- 2016/06/11 06:00
PHST- 2015/08/11 00:00 [received]
PHST- 2016/03/15 00:00 [revised]
PHST- 2016/05/03 00:00 [accepted]
PHST- 2016/06/11 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2016/06/11 06:00 [entrez]
AID - 10.1002/hon.2313 [doi]
PST - ppublish
SO  - Hematol Oncol. 2017 Dec;35(4):769-777. doi: 10.1002/hon.2313. Epub 2016 Jun 10.